Colinz Laboratories Share Price Today | Stock Price & Colinz Laboratories Share Screener
As of October 5, 2026, the live Colinz Laboratories share price (BSE: COLINZ) is ₹73.00, down 0.68% from the previous close, with shares trading between ₹72.50 and ₹73.00 in today's trading session, and a 52-week range of ₹39.75–₹85.92. Check COLINZ 52-week performance for the annual price range and momentum. Use the Colinz Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Colinz Laboratories opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹9 and net income of ₹3, with EBITDA of ₹4, an operating margin of 6.0% and a profit margin of 33.3%.
Colinz Laboratories Share Price Chart
Track the current stock price of Colinz Laboratories with an interactive chart. Analyse COLINZ share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Colinz Laboratories stock quote in one place.
The quote of ₹73.00 sits between the 52-week low of ₹39.75 and the 52-week high of ₹85.92, and the latest session moved -0.68% from the previous close.
Colinz Laboratories Company Profile - Fundamental Screener
Screen Colinz Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for COLINZ shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE923C01011.
Company Details
Classification
Identifiers and Leadership
Colinz Laboratories Balance Sheet Screener
Screen COLINZ balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹13, up from ₹12 in 2025.
Latest statistics put total assets at ₹13 and shareholder funds at ₹10, with a leverage ratio of 0.05.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 13 | 12 | 11 | 10 | 10 | 10 | 9 | 9 | 10 | 10 |
| Current Assets | 10 | 9 | 9 | 8 | 7 | 7 | 6 | 6 | 6 | 5 |
| Fixed Assets | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 10 | 10 | 9 | 8 | 8 | 7 | 7 | 7 | 7 | 7 |
| Share Capital | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves & Surplus | 8 | 7 | 6 | 6 | 4 | 4 | 3 | 3 | 3 | 3 |
Colinz Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Colinz Laboratories income statement and profit fundamentals. Analyze COLINZ quarterly results. Colinz Laboratories reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹9 and net profit was ₹3, equal to earnings per unit of ₹11.10, at an operating margin of 6%.
In that period expenses were ₹6, interest cost ₹0 and tax ₹1. The next period listed, 2026-March, shows revenue of ₹7 and net profit of ₹1.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 9 | 7 | 7 | 7 | 7 | 7 | 6 | 8 | 8 | 8 | 8 | 8 | 8 |
| Expenses | 6 | 6 | 6 | 7 | 7 | 6 | 6 | 7 | 7 | 8 | 8 | 8 | 7 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Operating Profit % | 6.00% | 7.00% | 8.00% | 8.00% | 9.00% | 8.00% | 5.00% | 4.00% | 5.00% | 5.00% | 5.00% | 6.00% | 6.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | 3 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS | 11.10 | 2.04 | 1.97 | 1.93 | 1.82 | 0.74 | 0.45 | -0.01 | 0.34 | 0.65 | 0.40 | 0.21 | 0.21 |
Colinz Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen COLINZ cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹3, and net cash flow was an inflow of ₹3.
Over the same period, investing activities provided ₹0 and financing activities provided ₹0.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 3 | -2 | 1 | 0 | 1 | 2 | 1 | 0 | 0 | 0 |
| Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Financing and Net Cash | ||||||||||
| Financing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Cash Flow | 3 | -2 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 0 |
Colinz Laboratories Shareholding Pattern Screener
See Colinz Laboratories shareholding pattern with promoter, FII, and DII holdings. Check Colinz Laboratories promoter holding and ownership changes for COLINZ on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Jun, promoters held 50.60%, foreign institutions 0.00%, domestic institutions 0.00% and the public 46.19%, spread across 3,174 shareholders.
The shareholder count was 3,174 in 2026-Jun, compared with 3,250 in 2026-Mar.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 50.60% | 66.00% | 66.00% | 66.00% | 66.00% | 66.00% | 66.00% | 66.00% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 46.19% | 31.22% | 31.01% | 30.97% | 31.04% | 30.44% | 31.01% | 31.04% |
| Other Holding | 3.21% | 2.78% | 2.99% | 3.03% | 2.95% | 3.56% | 2.99% | 2.96% |
| Shareholder Count | 3,174 | 3,250 | 3,212 | 3,272 | 3,238 | 3,216 | 3,202 | 3,116 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Colinz Laboratories. Colinz Laboratories dividend yield can be compared with peers and other stocks in the market.
Colinz Laboratories Stock Index Membership - Nifty & Sensex
See which indices include Colinz Laboratories stock. Check COLINZ index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Colinz Laboratories Market Events Screener - Corporate Actions
Get Colinz Laboratories corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Colinz Laboratories stock events that may affect COLINZ share price, along with derivatives, futures and options activity and sector gainers.
11 corporate actions are listed, the most recent entry being Annual General Meeting dated September 22, 2026, with a record date of September 22, 2026.
It is followed by Quarterly Result Announcement dated July 30, 2026 and Quarterly Result Announcement dated April 29, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-22 | 2026-09-22 | Annual General Meeting | NA | -5.20% |
| 2026-07-30 | 2026-07-30 | Quarterly Result Announcement | NA | 0.97% |
| 2026-04-29 | 2026-04-29 | Quarterly Result Announcement | NA | 0.00% |
| 2026-01-24 | 2026-01-24 | Quarterly Result Announcement | NA | -3.42% |
| 2025-11-03 | 2025-11-03 | Quarterly Result Announcement | NA | -1.94% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | -4.86% |
| 2025-07-31 | 2025-07-31 | Quarterly Result Announcement | NA | 12.74% |
| 2025-05-16 | 2025-05-16 | Quarterly Result Announcement | NA | 13.57% |
| 2025-01-31 | 2025-01-31 | Quarterly Result Announcement | NA | -3.37% |
| 2024-10-30 | 2024-10-30 | Quarterly Result Announcement | NA | 4.60% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | -8.26% |
Colinz Laboratories Competitors Screener - Peer Stocks Comparison
Screen COLINZ competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 427,178 | 35.84 | 61,674 | 12.69% | 11,565 | 36.68 |
| Divis Laboratories | 244,311 | 84.36 | 11,067 | 13.95% | 2,568 | 51.70 |
| Torrent Pharmaceuticals | 180,857 | 84.01 | 13,886 | 20.34% | 2,138 | 41.12 |
| Zydus Life Science | 113,865 | 24.88 | 27,658 | 17.64% | 5,026 | 47.64 |
| Cipla | 107,688 | 32.42 | 29,045 | 2.24% | 3,870 | 34.78 |
| Laurus Labs | 106,090 | 98.56 | 6,868 | 22.01% | 890 | 58.70 |
| Mankind Pharma | 102,869 | 50.48 | 14,636 | 14.85% | 1,938 | 61.75 |
| Dr Reddys Laboratories | 100,287 | 31.47 | 35,059 | 3.90% | 4,158 | 53.84 |
| Aurobindo Pharma | 96,364 | 25.97 | 34,145 | 5.56% | 3,503 | 50.30 |
| Lupin | 91,952 | 16.71 | 29,039 | 26.75% | 5,356 | 31.59 |
Colinz Laboratories Company Announcements - News & Reports Screener
Screen COLINZ latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 2, 2026.
The next most recent announcements are dated October 2, 2026 and September 30, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-02 | Declaration Of Non-Applicability Of Reg. 32 Of The SEBI (LODR) Regulations 2015 (Statement Of Deviation Or Variation For Proceeds Of Public Issue Rights Issue Preferential Issue QIP) For The Quarter Ended 30.09.2026. | - |
| 2026-10-02 | Declaration With Respect To Non-Applicability Of Related Party Transactions Pursuant To Regulations 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements Regulation 2015). | - |
| 2026-09-30 | Closure of Trading Window | - |
| 2026-09-23 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-09-22 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-04 | Post Offer Advertisement | - |
| 2026-08-27 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-20 | Reg. 34 (1) Annual Report. | - |
| 2026-08-20 | Notice Of Book Closure Under Regulation 42 Of SEBI (Listing Obligations And Disclosure Requirements) 2015 & E-Voting Schedule | - |
| 2026-08-20 | Notice Of 40Th AGM And Book Closure. | - |
| 2026-08-12 | Updates on Open Offer | - |
| 2026-08-06 | Updates on Open Offer | - |
| 2026-08-05 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-31 | Letter of Offer | - |
| 2026-07-31 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-30 | Outcome Of The Meeting Of Board Of Directors Was Held On Thursday 30Th July 2026 At 03:30 P.M. The Board Of Directors Discussed And/Or Approved The Following: | - |
| 2026-07-30 | Board Meeting Outcome for OUTCOME Of The Meeting Of Board Of Directors Was Held On Thursday 30Th July 2026 At 03:30 P.M. The Board Of Directors Discussed And/Or Approved The Following: | - |
| 2026-07-18 | Board Meeting Intimation for Notice Of Date Of Board Meeting Pursuant To Regulation 29(2) Of SEBI (LODR) Regulations 2015. | - |
| 2026-07-14 | Closure of Trading Window | - |
| 2026-07-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹73.00, within a 52-week range of ₹39.75 to ₹85.92. The P/E ratio is 6.62 and the P/B ratio is 1.84, with earnings per unit of ₹2.04. Market capitalisation stands at ₹18.37 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.